Key Points
- Director Chee Kong Choo bought 112,000 shares of CytoMed Therapeutics at $1.15 per share, a transaction worth $128,800. The purchase increased his holdings by 35.18% to 430,324 shares.
- GDTC shares were up 1.0% and opened at $1.15, near the stock’s 50-day moving average of $1.04 and 200-day moving average of $1.16. The stock has traded between $0.68 and $3.68 over the past 12 months.
- Analysts remain bearish on CytoMed Therapeutics, with Weiss Ratings reiterating a “sell (e+)” rating and MarketBeat showing a consensus rating of “Sell.” The company most recently reported a quarterly loss of $0.06 per share on minimal revenue.
CytoMed Therapeutics Limited (NASDAQ:GDTC - Get Free Report) Director Chee Kong Choo purchased 112,000 shares of the company's stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average price of $1.15 per share, with a total value of $128,800.00. Following the transaction, the director owned 430,324 shares of the company's stock, valued at $494,872.60. This represents a 35.18% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
CytoMed Therapeutics Trading Up 1.0%
GDTC opened at $1.15 on Tuesday. CytoMed Therapeutics Limited has a 12 month low of $0.68 and a 12 month high of $3.68. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average of $1.04 and a 200 day moving average of $1.16.
CytoMed Therapeutics (NASDAQ:GDTC - Get Free Report) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.06) EPS for the quarter. The company had revenue of $0.06 million during the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of CytoMed Therapeutics in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CytoMed Therapeutics currently has a consensus rating of "Sell".
Get Our Latest Analysis on GDTC
CytoMed Therapeutics Company Profile
(
Get Free Report)
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
